home | datasets | contacts and credits |
feature | meaning | type | values |
---|---|---|---|
Age at diagnosis | age at diagnosis | months | 2, ..., 196 |
Ferritin | ferritin serum level | ng/ml | -99, 19, ..., 2250 |
Histologic category | Histologic category | categorical | NS, NB, GNB |
INRG Risk classification | risk group: HR: high risk | categorical (only one value) | 1 |
INSS Stage | Stage of the tumor (only stage 4 patients) | categorical (only one value) | 1 |
Methylation PCDHB cluster (%) | methylation of 17 genes of the Protocadherin B cluster | percentage | 29.44, ..., 88.93 |
Methylation SFN (%) | methylation of the SFN gene | percentage | 36.6, ..., 99 |
MYCN amplification | Status of nMYC oncogene: 0, amplified, 1, unamplified; | binary | 0, 1 |
OS | overall survival | months | 0.27, ..., 164.47 |
Outcome | Clinical Outcome | categorical | AICR, AWD, AWSD, CR, DOD |
PFS | progression free survival | months | 3.7, ...., 74.7, NaN |
feature | meaning | type | values |
---|---|---|---|
11q- | presence of chromosomal aberration at 11q site | boolean | yes, no, - |
171+ | presence of chromosomal aberration at 17q site | boolean | yes, no, - |
1p- | presence of chromosomal aberration at 1p site | boolean | yes, no, - |
age | age | months | 0, ..., 10.2 |
Ferritin | ferritin levels | ng/mL | 15, ..., 1638.6 |
LDH | lactic acid dehydrogenase levels | U/L | 539, ..., 6200 |
Local RTx dose (gy) | dosage of radiation | float | 15, 23.4, 25.2, - |
Metastatic sites | site of metastsoization | categorical | BM, bone, kidney, liver, LN, lung, |
mediastinum, muscle, pleura, skin | |||
NSE | neuron-specific enolase levels | float | 7.3, ..., 947 |
Outcome | alive or dead | boolean | NED, EFS |
Outcome_mo | follow-up | monhths | 17, ..., 91 |
Primary site | tumor primary site | binary | abdomen, mediastinum |
Sex | F/M | binary | M/F |
Tumor response after CT & S | patient response after chemotheraphy and surgey | categorical | CR, MR, PR, VGPR |
Tumor response after DT | patient response after differentiation theraphy (DT) | categorical | CR, MR, PR, VGPR |
Urine VMA | vanillylmandelic acid levels in urine | mg/day | 0.5, ..., 53.9 |
feature | meaning | type | values |
---|---|---|---|
Age at diagnosis | age | months | 9, ..., 108 |
Follow-up time | Overall survival | months | 1, ..., 132 |
ID | ID | integer | code |
Metastases | Presence of metastasis | boolean | yes, no |
Outcome | Clinical outcome | categorical | ADF, AWD, DOD, DOS, DTC |
Pathology | Patological category | categorical | nGNB, pdNB, uNB |
Protocol Treatment | Treatment protocol | categorical | HR-NBL1, INES, LNESG1, N-II-92, NAR-99 |
Relapse | relapsed Yes or no | boolean | yes/no |
Sex | M/F | binary | M/F |
Stage | Stage of the tumor | categorical | 1, 2, 3, 4 |
Interval to first relapse | Interval to first relapse | months | 4, ..., 28 |
Treatment Response | treatmnent response | categorical | CR, DP, PR, SurPR, VGPR |
feature | meaning | type | values |
---|---|---|---|
Age at Dx. | Age of the patient at diagnosis | years | 1.5, ..., 3.5 |
Age at relapse | Age of the patient at relapse | years | 4.1, ..., 8.6 |
HDCT1 regimen | first high-dose chemotherapy | binary | TTC, CEC |
HDCT2 regimen | second high-dose chemotherapy | binary | MEC, MIBG-TM |
Interval to relapse | Interval (m) to relapse | months | 12, ..., 75 |
MYCN status | amplified (A) or not amplified (NA) | binary | A, NA |
Relapsed sites | relapse sites in the body | categorical | Primary, Brain, bone, LNs, BM |
Stage at Dx | only metastistic tumors | categorical | 4 |
Treatment prior to haplo-SCT | treatment prior to haploidentical stem cell transplantation |
categorical | Surgery, L-RT, CT×5, CT×6, CT×7 |
Tumor status at haplo-SCT | tumor status at athaploidentical stem cell transplantation |
categorical | PR, CR, VGPR |
feature | meaning | type | values |
---|---|---|---|
age | <12 months, 1, 12–60 months, 2, ≥60 months; | integer | 0, 1, 2 |
autologous stem cell transplantation | Autologous stem cell transplantation: 0: no, 1: yes. | binary | 0, 1 |
degree of differentiation | Degree of differentiation: 0: undifferentiated subtype; | categorical | 0, 1, 2 |
1: poorly differentiated subtype; 2: differentiating subtype; | |||
histology prognosis | 1: FH favorable histology, 0: UF unfavorable histology | binary | 0, 1 |
MYCN status | Status of nMYC oncogene: 0, amplified, 1, unamplified; | binary | 0, 1 |
outcome | Clinical Outcome: 1, dead of disease, 0, alive or lost follow-up; | binary | 0, 1 |
radiation | Radiation: 0, no, 1, yes; | binary | 0, 1 |
Risk | Risk group: 0: intermediate-risk; 1: high-risk. | categorical | 0, 1 |
sex | 0: male; 1: female | integer | 0, 1 |
site | primary tumor Site: 0, adrenal gland, 1, mediastinum, 2, others. | categorical | 0, 1, 2 |
stage | Stage of the tumor | categorical | 1, 2, 3, 4 |
surgical methods | total or partial resection | binary | 0, 1 |
time | overall survival | months | 1, ..., 100 |